期刊文献+

儿童用药的药物警戒特征和模式探讨 被引量:4

Characteristics and Working Model for Pharmacovigilance of Pediatric Medication
下载PDF
导出
摘要 目的论述开展儿童药物警戒工作的重要性、特征以及方法,探索儿童用药药物警戒模式。方法根据欧洲药品管理局发布的儿童用药药物警戒指南,分析儿童用药的特征。结果儿童用药不良事件潜在发生率不低于成人,而且,儿童用药的不良反应特征与成人相比有差异。结论应结合我国儿童用药不良反应监测工作现状,建立科学的儿童用药不良反应监测模式。 Objective To expound the importance, characteristics and practice of pharmacovigilance of medicines used in pediatric population and discuss its working model. Methods The characteristics of pediatric medication were analyzed using "Guideline on Conduct of Pharmacovigilance for Medicines Used by the Pediatric Population" released by EMEA as a reference. Results The rate of occurrence of ADRs in pediatric population is no lower than that in adults and ADR characteristics in pediatric population are different from those in adults. Conclusion China should establish the working model for pharmacovigilance of medicines used in pediatric population according to the current status of ADR monitoring system.
出处 《中国药事》 CAS 2013年第6期557-560,共4页 Chinese Pharmaceutical Affairs
关键词 儿童用药 药物警戒 工作模式 pediatric medication pharmacovigilance working model
  • 相关文献

参考文献12

  • 1Rashed, Asia N, Wong, et al. Adverse Drug Reactions in Children-International Surveillance and Evaluation (AD- VISE) [J]. A Muhicentre Cohort Study, Drug SaG 2012 , 35 (6): 481-94. 被引量:1
  • 2EMEA. GUIDELINE ON CONDUCT OF PHARMACOVIGI- LANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION [EB/OL]. [2013-02-25]. http: //www. eros. europa, eu/docs. 被引量:1
  • 3ICH. ICH Ell Note for Guidance on the Clinical Investiga- tion of Medicinal Products in the Paediatrie Population (CPMP/ICH/2711/99) [EB/OL]. (2000-01-05) [2010-12- 25 ]. http: //www. ema. europa, eu/docs/en GB/docu- ment _ library/Scientific _ guideline/2009/09/WCS00002926. pdf. 被引量:1
  • 4吴世启,王强.儿童用药现状浅析[J].中国药事,2012,26(7):787-789. 被引量:32
  • 5左秀萍,高晖.我国儿童用药现状分析[J].中国药事,2002,16(9):575-575. 被引量:6
  • 6张蕾,王永铭,陈斌艳,沈刚.儿童药物不良反应研究[J].中国临床药理学杂志,1996,12(1):39-45. 被引量:44
  • 7EMEA. CHMP Guideline on Risk Management System for Medicinal Products for Human Use (EMEA/CHMP/96268/ 2005) [EB/OL]. (2005-11-14) [2011-01-01]. http: // www. ema. europa, eu/docs/en _ GB/document _ library/Regula- tory_ and_ procedural_ guideline/2009/10/WCS00004888, pdf. 被引量:1
  • 8孙忠实,朱珠.提高儿童用药安全性的警戒[J].中国药物警戒,2004,1(1):28-30. 被引量:18
  • 9张志华,何周康,吴浩.药品说明书中有关儿童用药内容的调查[J].儿科药学杂志,2004,10(5):41-42. 被引量:33
  • 10EMEA. CHMP guideline on conduct of pharmacovigilanee for medicines used by the pediatric population (EMEA/ CHMP/PhVWP/235910/2005- rev. 1 [EB/OL]. (2006 03- 01) [2011-01-01]. http: //www. erna. europa, eu/does/ en _ GB/doeument _ library/Scientific _ guideline/2009/09/ WC500003764. pdf. 被引量:1

二级参考文献12

共引文献126

同被引文献52

  • 1张宇靖,张昌斌.197例儿童药品不良反应报告分析[J].药物不良反应杂志,2005,7(5):379-381. 被引量:34
  • 2黄志华.重视儿科合理用药[J].中国临床医生杂志,2006,34(2):12-14. 被引量:52
  • 3European Medicines Agency.5-Year Report to the European Commission[EB/OL].[2012-07-08].http://ec.europa.eu/health/files/paediatrics/2012-09_pediatric_report-annex1-2_en.pdf. 被引量:1
  • 4European Medicines Agency.The European paediatric initiative:History of the Paediatric Regulation[EB/OL].[2007-07-11].http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/09/WC500003693.pdf. 被引量:1
  • 5Jochen Zisowsky,Andreas Krause,Jasper Dingemanse.Drug Development for Pediatric Populations:Regulatory Aspects[J].Pharmaceutics,2010,2(4):364-388. 被引量:1
  • 6European Medicines Agency.Report to the European Commission:Companies and products that have benefited from any of the rewards and incentives in the pediatric regulation and the companies that have failed to comply with any of the obligations in Pharmaceutics 2010,2384 this regulation covering the years 2007 to 2009(EMA/50813/2009).[EB/OL].[2010-04-27].http://ec.europa.eu/health/files/paediatrics/article_50_report2010.pdf. 被引量:1
  • 7European Medicines Agency.EudraVigilance[EB/OL].http://www.ema.europa.eu/ema/index.jspcurl=pages/regulation/document_listing/document_listing_000239.jsp&mid=WC0b01ac05800250b5. 被引量:1
  • 8国务院:国务院关于印发中国妇女发展纲要和中国儿童发展纲要的通知(国发[2011]24号)[EB/OL].[2011-08-08].http://www.gov.cn/zwgk/2011-08/08/content_1920457.html. 被引量:1
  • 9国务院:国务院关于印发国家药品安全"十二五"规划的通知[国发(2012)5号][EB/OL].[2012-02-13] http://www.gov.cn/zwgk/2012-02/13/ content_2065197.html. 被引量:1
  • 10国家食品药品监督管理局:关于深化药品审评审批改革进一步鼓励药物创新的意见(国食药监注[2013]37号)[EB/OL].[2013-02-22].http://www.sfda.gov.cn/WS01/CL0844/78576.html. 被引量:1

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部